Cargando…

The Genetic, Environmental, and Immunopathological Complexity of Autoantibody-Negative Rheumatoid Arthritis

Differences in clinical presentation, response to treatment, and long-term outcomes between autoantibody-positive and -negative rheumatoid arthritis (RA) highlight the need for a better comprehension of the immunopathogenic events underlying the two disease subtypes. Whilst the drivers and perpetuat...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Stefano, Ludovico, D’Onofrio, Bernardo, Manzo, Antonio, Montecucco, Carlomaurizio, Bugatti, Serena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618508/ https://www.ncbi.nlm.nih.gov/pubmed/34830268 http://dx.doi.org/10.3390/ijms222212386

Ejemplares similares

Personalized Therapeutic Strategies in the Management of Osteoporosis in Patients with Autoantibody-Positive Rheumatoid Arthritis
por: D’Onofrio, Bernardo, et al.
Publicado: (2022)

The Clinical Value of Autoantibodies in Rheumatoid Arthritis
por: Bugatti, Serena, et al.
Publicado: (2018)

Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis
por: Bugatti, Serena, et al.
Publicado: (2021)

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
por: Bobbio-Pallavicini, Francesca, et al.
Publicado: (2004)

Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective
por: Bugatti, Serena, et al.
Publicado: (2012)

B Cells in Rheumatoid Arthritis: From Pathogenic Players to Disease Biomarkers
por: Bugatti, Serena, et al.
Publicado: (2014)

Impact of Anti-Citrullinated Protein Antibodies on Progressive Systemic Bone Mineral Density Loss in Patients With Early Rheumatoid Arthritis After Two Years of Treat-to-Target
por: Bugatti, Serena, et al.
Publicado: (2021)

Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis
por: Bugatti, Serena, et al.
Publicado: (2016)

Rheumatoid arthritis treatment: the earlier the better to prevent joint damage
por: Monti, Sara, et al.
Publicado: (2015)

The Draining Lymph Node in Rheumatoid Arthritis: Current Concepts and Research Perspectives
por: Benaglio, Francesca, et al.
Publicado: (2015)

Insights Into the Concept of Rheumatoid Arthritis Flare
por: Bozzalla-Cassione, Emanuele, et al.
Publicado: (2022)

No evidence of short-term impact of repeated BNT162b2 vaccination on rheumatoid arthritis homeostasis in drug-free remission
por: Bozzalla Cassione, Emanuele, et al.
Publicado: (2022)

A “Window of Therapeutic Opportunity” for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019
por: De Stefano, Ludovico, et al.
Publicado: (2020)

Janus kinase inhibitors effectively improve pain across different disease activity states in rheumatoid arthritis
por: De Stefano, Ludovico, et al.
Publicado: (2023)

The access route through the anatomical snuffbox in ultrasound-guided synovial biopsy of the wrist allows for a safe and effective collection of tissue samples in inflammatory arthritis
por: De Stefano, Ludovico, et al.
Publicado: (2023)

Power Doppler ultrasonographic assessment of the joint-draining lymph node complex in rheumatoid arthritis: a prospective, proof-of-concept study on treatment with tumor necrosis factor inhibitors
por: Manzo, Antonio, et al.
Publicado: (2016)

Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs
por: Bugatti, Serena, et al.
Publicado: (2012)

Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline
por: Bugatti, Serena, et al.
Publicado: (2020)

Long-term efficacy and safety of biologics in rheumatoid arthritis
por: Montecucco, Carlomaurizio
Publicado: (2012)

Impact of csDMARDs adherence on clinical remission in patients with new-onset inflammatory arthritis: a prospective cohort study from the ELECTRA database
por: Zanetti, Anna, et al.
Publicado: (2023)

In Patients with Early Peripheral Psoriatic Arthritis Baseline C-Reactive Protein, Pain and Ultrasound-Detected Synovitis Predict Subsequent Treatment with ts/bDMARDs. A Retrospective Analysis
por: Sakellariou, Garifallia, et al.
Publicado: (2021)

Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable?
por: Bugatti, Serena, et al.
Publicado: (2018)

Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure
por: Scirè, Carlo Alberto, et al.
Publicado: (2007)

Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics
por: Conti, Valeria, et al.
Publicado: (2020)

Influence of initial glucocorticoid co-medication on mortality and hospitalization in early inflammatory arthritis: an investigation by record linkage of clinical and administrative databases
por: Sakellariou, Garifallia, et al.
Publicado: (2022)

Performance of the 2010 Classification Criteria for Rheumatoid Arthritis: A Systematic Literature Review and a Meta-Analysis
por: Sakellariou, Garifallia, et al.
Publicado: (2013)

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Nathalie, Luurssen-Masurel, et al.
Publicado: (2021)

Cardiovascular Comorbidities Relate More than Others with Disease Activity in Rheumatoid Arthritis
por: Crepaldi, Gloria, et al.
Publicado: (2016)

Autoantibodies in rheumatoid arthritis and their clinical significance
por: Steiner, Günter, et al.
Publicado: (2002)

New autoantibodies in early rheumatoid arthritis
por: Charpin, Caroline, et al.
Publicado: (2013)

Autoantibodies to Posttranslational Modifications in Rheumatoid Arthritis
por: Burska, Agata N., et al.
Publicado: (2014)

The role of autoantibodies in the pathophysiology of rheumatoid arthritis
por: Derksen, V. F. A. M., et al.
Publicado: (2017)

Therapeutic implications of autoantibodies in rheumatoid arthritis
por: Aletaha, Daniel, et al.
Publicado: (2016)

Correction to: Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Luurssen-Masurel, Nathalie, et al.
Publicado: (2022)

Immunopathologic characterization of ultrasound-defined synovitis in rheumatoid arthritis patients in clinical remission
por: Ramírez, Julio, et al.
Publicado: (2016)

Osteopontin: A Bone-Derived Protein Involved in Rheumatoid Arthritis and Osteoarthritis Immunopathology
por: Martín-Márquez, Beatriz Teresita, et al.
Publicado: (2023)

Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study
por: Montecucco, Carlomaurizio, et al.
Publicado: (2012)

Autoantibodies to BRAF, a new family of autoantibodies associated with rheumatoid arthritis
por: Charpin, Caroline, et al.
Publicado: (2010)

Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis
por: Favalli, Ennio Giulio, et al.
Publicado: (2020)

Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies
por: Song, Y.W., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ud3s9slrvredsulgl3fq435riv